

May 20, 2022

Ceftazidime for Injection & Sodium Chloride Injection Availability Notice

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that all formats of our **Ceftazidime for Injection, USP** will be available at all distribution centres effective **May 26, 2022**.

Our **Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL** will be available at all distribution centres effective **May 19, 2022**. Once available, this product will be placed on allocation. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Availability Date
00886971	VL7231	920472	425801	Ceftazidime for Injection, USP 1 g SD Vial 20 mL	All distribution centres by: May 26, 2022
00886955	VL7234	920484	425942	Ceftazidime for Injection, USP 2 g SD Vial 50 mL	All distribution centres by: May 26, 2022
00886963	VL7241	920496	425694	Ceftazidime for Injection, USP 6 g PBP Vial 100 mL	All distribution centres by: May 26, 2022
02139510	C88B2	922869	594234	Sodium Chloride Injection, USP 4 mEq/mL Maxivial® 200 mL*	All distribution centres by: May 19, 2022

*Once available, this product will be on 100% allocation.

Thank you for your patience and understanding during our supply disruption and please do not hesitate to contact your sales representative with any questions or concerns.

Sincerely,



George Shamsoun
 Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com